期刊
ANNALS OF ONCOLOGY
卷 26, 期 12, 页码 2367-2374出版社
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdv382
关键词
immunotherapy; cancer; next-generation sequencing; personalized oncology; T cell; neoantigen
类别
资金
- Canadian Institutes of Health Research [MOP 84463] Funding Source: Medline
- NCI NIH HHS [R01CA156695] Funding Source: Medline
Genomic technologies have enabled personalized cancer treatments based on the unique molecular aberrations in each person's tumor. T-cell-based immunotherapies may expand the range of therapeutic options for personalized oncology. Here, we discuss the advantages of targeting T cells towards mutations, and the identification and potential therapeutic utilization of mutation-reactive T cells.Owing to recent advances in genomic technologies, personalized oncology is poised to fundamentally alter cancer therapy. In this paradigm, the mutational and transcriptional profiles of tumors are assessed, and personalized treatments are designed based on the specific molecular abnormalities relevant to each patient's cancer. To date, such approaches have yielded impressive clinical responses in some patients. However, a major limitation of this strategy has also been revealed: the vast majority of tumor mutations are not targetable by current pharmacological approaches. Immunotherapy offers a promising alternative to exploit tumor mutations as targets for clinical intervention. Mutated proteins can give rise to novel antigens (called neoantigens) that are recognized with high specificity by patient T cells. Indeed, neoantigen-specific T cells have been shown to underlie clinical responses to many standard treatments and immunotherapeutic interventions. Moreover, studies in mouse models targeting neoantigens, and early results from clinical trials, have established proof of concept for personalized immunotherapies targeting next-generation sequencing identified neoantigens. Here, we review basic immunological principles related to T-cell recognition of neoantigens, and we examine recent studies that use genomic data to design personalized immunotherapies. We discuss the opportunities and challenges that lie ahead on the road to improving patient outcomes by incorporating immunotherapy into the paradigm of personalized oncology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据